Concepedia

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

Joyce F. Liu, Sara M. Tolaney, Michael J. Birrer, Gini F. Fleming, Mary K. Buss, Suzanne E. Dahlberg, Hang Lee, Christin Whalen, Karin Tyburski, Eric P. Winer,

European Journal of Cancer · 2013 · 172 citations · 18 references

DOIFull text

Open access

Concepts

References

18

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations

, , +16

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Helen E. Bryant, Niklas Schultz, Huw D. Thomas et al. · Nature · 2005 · 5.2K citations

, , +12

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · New England Journal of Medicine · 2009 · 3.6K citations · Full text

, , +17

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

Kathy D. Miller, Molin Wang, Julie R. Gralow et al. · New England Journal of Medicine · 2007 · 3.1K citations · Full text

, , +13

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

M. William Audeh, James Carmichael, Richard T. Penson et al. · The Lancet · 2010 · 2.3K citations

, , +16